• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在抑制甲硫氨酸成瘾性骨肉瘤细胞增殖的浓度下,重组蛋氨酸酶可降低组蛋白H3赖氨酸三甲基化标记物水平,而甲氨蝶呤则可使其升高。

Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation.

作者信息

Aoki Yusuke, Tome Yasunori, Han Qinghong, Yamamoto Jun, Hamada Kazuyuki, Masaki Noriyuki, Bouvet Michael, Nishida Kotaro, Hoffman Robert M

机构信息

AntiCancer Inc, 7917 Ostrow St, San Diego, CA, 92111, USA.

Department of Surgery, University of California, San Diego, 9300 Campus Point Drive #7220, La Jolla, CA, 92037-7220, USA.

出版信息

Biochem Biophys Rep. 2021 Nov 26;28:101177. doi: 10.1016/j.bbrep.2021.101177. eCollection 2021 Dec.

DOI:10.1016/j.bbrep.2021.101177
PMID:34877414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8633566/
Abstract

Methionine addiction is a fundamental and general hallmark of cancer cells, which require exogenous methionine, despite their ability to synthesize normal amounts of methionine from homocysteine. In contrast, methionine-independent normal cells do not require exogenous methionine in the presence of a methionine precursor. The methionine addiction of cancer cells is due to excess transmethylation reactions. We have previously shown that histone H3 lysine marks are over-methylated in cancer cells and the over-methylation is unstable when the cancer cells are restricted of methionine. In the present study, we show that methionine-addicted osteosarcoma cells are sensitive to both methotrexate (MTX) and recombinant methioninase (rMETase), but they affect histone H3 lysine-methylation in the opposite direction. Concentrations of MTX and rMETase, which inhibit osteosarcoma cells viability to 20%, had opposing effects on the status of histone methylation of H3K9me3 and H3K27me3. rMETase significantly decreased the amount of H3K9me3 and H3K27me3. In contrast, MTX significantly increased the amount of H3K9me and H3K27me3. The results suggest that increase or decrease in these methylated histone lysine marks is associated with proliferation arrest of methionine-addicted osteosarcoma.

摘要

甲硫氨酸成瘾是癌细胞的一个基本且普遍的特征,尽管癌细胞有能力从同型半胱氨酸合成正常量的甲硫氨酸,但它们仍需要外源性甲硫氨酸。相比之下,不依赖甲硫氨酸的正常细胞在有甲硫氨酸前体存在时不需要外源性甲硫氨酸。癌细胞的甲硫氨酸成瘾是由于过量的转甲基反应。我们之前已经表明,癌细胞中组蛋白H3赖氨酸标记过度甲基化,并且当癌细胞的甲硫氨酸受到限制时,这种过度甲基化是不稳定的。在本研究中,我们表明对甲硫氨酸成瘾的骨肉瘤细胞对甲氨蝶呤(MTX)和重组甲硫氨酸酶(rMETase)均敏感,但它们对组蛋白H3赖氨酸甲基化的影响方向相反。抑制骨肉瘤细胞活力至20%的MTX和rMETase浓度,对H3K9me3和H3K27me3组蛋白甲基化状态有相反的影响。rMETase显著降低了H3K9me3和H3K27me3的量。相比之下,MTX显著增加了H3K9me和H3K27me3的量。结果表明,这些甲基化组蛋白赖氨酸标记的增加或减少与对甲硫氨酸成瘾的骨肉瘤的增殖停滞有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e527/8633566/6343407c08d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e527/8633566/208d7b78aa6f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e527/8633566/6343407c08d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e527/8633566/208d7b78aa6f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e527/8633566/6343407c08d0/gr2.jpg

相似文献

1
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation.在抑制甲硫氨酸成瘾性骨肉瘤细胞增殖的浓度下,重组蛋氨酸酶可降低组蛋白H3赖氨酸三甲基化标记物水平,而甲氨蝶呤则可使其升高。
Biochem Biophys Rep. 2021 Nov 26;28:101177. doi: 10.1016/j.bbrep.2021.101177. eCollection 2021 Dec.
2
Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.组蛋白 H3 赖氨酸三甲基化的程度和不稳定性随恶性程度和蛋氨酸依赖性增加。
Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):12-18. doi: 10.21873/cgp.20299.
3
Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation.骨肉瘤细胞从甲硫氨酸成瘾状态转变为甲硫氨酸非依赖状态会导致恶性程度丧失、上皮-间质表型的调节以及组蛋白H3赖氨酸甲基化的改变。
Front Oncol. 2022 Nov 3;12:1009548. doi: 10.3389/fonc.2022.1009548. eCollection 2022.
4
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.甲硫氨酸限制下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在甲硫氨酸成瘾性癌细胞中不稳定,但在正常细胞中稳定。
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
5
Loss of Malignancy of Super-Methotrexate-resistant Osteosarcoma Cells Is Associated With an Increase of Methylated Histone Marks H3K9me3 and H3K27me3.超甲氨蝶呤耐药骨肉瘤细胞的去恶性化与组蛋白标记 H3K9me3 和 H3K27me3 的甲基化增加有关。
Anticancer Res. 2024 Oct;44(10):4213-4218. doi: 10.21873/anticanres.17251.
6
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of .蛋氨酸酶和乙硫氨酸联合利用蛋氨酸成瘾选择性消除骨肉瘤细胞而不杀伤正常细胞,并协同下调表达。
Cancer Genomics Proteomics. 2023 Dec;20(6suppl):679-685. doi: 10.21873/cgp.20415.
7
Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.口服重组甲硫氨酸酶使患者来源的原位异种移植(PDOX)小鼠模型中的骨肉瘤从耐甲氨蝶呤转变为敏感。
Anticancer Res. 2022 Feb;42(2):731-737. doi: 10.21873/anticanres.15531.
8
Deletion of Highly Sensitizes Osteosarcoma Cells to Methionine Restriction With Recombinant Methioninase.缺失高度敏感骨肉瘤细胞对蛋氨酸限制与重组蛋氨酸酶。
Cancer Genomics Proteomics. 2022 May-Jun;19(3):299-304. doi: 10.21873/cgp.20321.
9
Linkage of methionine addiction, histone lysine hypermethylation, and malignancy.蛋氨酸成瘾、组蛋白赖氨酸高甲基化与恶性肿瘤的关联。
iScience. 2022 Mar 25;25(4):104162. doi: 10.1016/j.isci.2022.104162. eCollection 2022 Apr 15.
10
Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse Model.口腔重组蛋氨酸酶降低顺铂对乳腺原发性骨肉瘤患者来源原位异种移植模型的有效剂量并消除其毒性。
In Vivo. 2022 Nov-Dec;36(6):2598-2603. doi: 10.21873/invivo.12994.

引用本文的文献

1
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.癌症中的甲硫氨酸依赖性与限制:探索致病功能和治疗潜力
Pharmaceuticals (Basel). 2025 Apr 28;18(5):640. doi: 10.3390/ph18050640.
2
Targeting Methionine Addiction of Osteosarcoma with Methionine Restriction to Overcome Drug Resistance: A New Paradigm for a Recalcitrant Disease.通过限制甲硫氨酸靶向骨肉瘤的甲硫氨酸成瘾以克服耐药性:一种针对难治性疾病的新范式
Cancers (Basel). 2025 Feb 3;17(3):506. doi: 10.3390/cancers17030506.
3
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease.

本文引用的文献

1
HOTAIR promotes gefitinib resistance through modification of EZH2 and silencing p16 and p21 in non-small cell lung cancer.HOTAIR通过修饰EZH2以及沉默非小细胞肺癌中的p16和p21来促进吉非替尼耐药。
J Cancer. 2021 Jul 25;12(18):5562-5572. doi: 10.7150/jca.56093. eCollection 2021.
2
Oral-recombinant Methioninase Converts an Osteosarcoma from Docetaxel-resistant to -Sensitive in a Clinically-relevant Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.口服重组蛋氨酸酶在临床相关的患者源性原位异种移植(PDOX)小鼠模型中,可将骨肉瘤从多西他赛耐药转变为敏感。
Anticancer Res. 2021 Apr;41(4):1745-1751. doi: 10.21873/anticanres.14939.
3
表达c-MYC且获得吉西他滨耐药性的纤维肉瘤细胞对重组蛋氨酸酶仍敏感:一种针对难治性疾病的潜在临床策略。
Cancer Diagn Progn. 2025 Jan 3;5(1):8-14. doi: 10.21873/cdp.10405. eCollection 2025 Jan-Feb.
4
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models.在裸鼠模型中使用蛋氨酸限制联合异环磷酰胺协同根除具有获得性异环磷酰胺耐药性的纤维肉瘤
In Vivo. 2025 Jan-Feb;39(1):120-126. doi: 10.21873/invivo.13809.
5
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model.在裸鼠模型中,与单独使用高剂量伊立替康相比,靶向蛋氨酸成瘾联合低剂量伊立替康可有效抑制结直肠癌,而高剂量伊立替康则无效。
In Vivo. 2024 May-Jun;38(3):1058-1063. doi: 10.21873/invivo.13539.
6
Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.替莫唑胺联合放疗联合口服重组甲硫氨酸酶和低甲硫氨酸饮食治疗高级别胶质瘤的青少年女性患者的广泛退缩和长期稳定疾病。
In Vivo. 2024 May-Jun;38(3):1459-1464. doi: 10.21873/invivo.13591.
7
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of .蛋氨酸酶和乙硫氨酸联合利用蛋氨酸成瘾选择性消除骨肉瘤细胞而不杀伤正常细胞,并协同下调表达。
Cancer Genomics Proteomics. 2023 Dec;20(6suppl):679-685. doi: 10.21873/cgp.20415.
8
Recombinant-methioninase-producing Instilled in the Microbiome Inhibits Triple-negative Breast Cancer in an Orthotopic Cell-line Mouse Model.在原位细胞系小鼠模型中,向微生物群中注入产重组蛋氨酸酶的物质可抑制三阴性乳腺癌。
Cancer Diagn Progn. 2023 Nov 3;3(6):649-654. doi: 10.21873/cdp.10267. eCollection 2023 Nov-Dec.
9
Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.重组甲硫氨酸酶降低瑞戈非尼对结肠癌细胞的有效剂量:一种有毒药物广泛临床应用的策略。
Cancer Diagn Progn. 2023 Nov 3;3(6):655-659. doi: 10.21873/cdp.10268. eCollection 2023 Nov-Dec.
10
Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.蛋氨酸限制与化疗联合的协同作用:颠覆性的下一代癌症治疗方法。
Cancer Diagn Progn. 2023 May 3;3(3):272-281. doi: 10.21873/cdp.10212. eCollection 2023 May-Jun.
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer.
联合甲硫氨酸甲基化轴阻断:一种针对癌症甲硫氨酸成瘾的新方法。
Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):113-120. doi: 10.21873/cgp.20246.
4
Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells.甲硫氨酸限制下 H3K4me3 和 H3K9me3 的组蛋白甲基化状态在甲硫氨酸成瘾性癌细胞中不稳定,但在正常细胞中稳定。
Biochem Biophys Res Commun. 2020 Dec 17;533(4):1034-1038. doi: 10.1016/j.bbrc.2020.09.108. Epub 2020 Oct 3.
5
Histone methyltransferase and drug resistance in cancers.组蛋白甲基转移酶与癌症的耐药性。
J Exp Clin Cancer Res. 2020 Aug 28;39(1):173. doi: 10.1186/s13046-020-01682-z.
6
EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.EZH2 介导的肿瘤抑制因子 DAB2IP 下调维持卵巢癌细胞干细胞。
Cancer Res. 2020 Oct 15;80(20):4371-4385. doi: 10.1158/0008-5472.CAN-20-0458. Epub 2020 Aug 19.
7
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.靶向 KDM4B-AR-c-Myc 轴可提高晚期前列腺癌对雄激素受体靶向治疗的敏感性。
J Pathol. 2020 Oct;252(2):101-113. doi: 10.1002/path.5495. Epub 2020 Aug 28.
8
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.口服重组甲硫氨酸酶可使骨转移前列腺癌患者 PSA 降低 70%,晚期卵巢癌患者血循环中甲硫氨酸降低 50%。
Anticancer Res. 2020 May;40(5):2813-2819. doi: 10.21873/anticanres.14254.
9
Recombinant Methioninase Combined With Tumor-targeting A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma.重组甲硫氨酸酶联合肿瘤靶向 A1-R 诱导多柔比星耐药去分化脂肪肉瘤 PDOX 小鼠模型的消退。
Anticancer Res. 2020 May;40(5):2515-2523. doi: 10.21873/anticanres.14222.
10
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.口服重组甲硫氨酸酶和地西他滨联合治疗耐药性未分化软组织肉瘤患者来源的原位异种移植小鼠模型。
Biochem Biophys Res Commun. 2020 Feb 26;523(1):135-139. doi: 10.1016/j.bbrc.2019.12.024. Epub 2019 Dec 12.